Forest-Trevena Ink Deal - Analyst Blog
May 14 2013 - 7:40AM
Zacks
Forest Laboratories
Inc. (FRX) recently signed a collaborative licensing
option deal with Trevena, Inc. for the latter’s mid-stage candidate
TRV027.
TRV027 is being developed for the
treatment of acute decompensated heart failure (ADHF). Results on
the candidate from a phase IIa study in patients with advanced
heart failure with reduced ejection fraction showed that TRV027 was
generally well-tolerated and demonstrated a beneficial set of
hemodynamic effects.
TRV027 is slated to move into a
multi-center phase IIb study in ADHF patients by year end. This
study will be funded by Trevena. Once this study is completed,
Forest Labs will have the option to exclusively license TRV027 on a
global basis.
Additional
Details
Although detailed financial
information was not provided, Forest Labs will make a $30 million
equity investment in Trevena. Once Forest Labs exercises its
option, it may pay up to $430 million on the achievement of
development and commercial milestones. Trevena will also be
entitled to royalties. Forest Labs will also be responsible for the
development and commercialization of TRV027. Trevena’s $60 million
Series C financing round will be led by Forest Labs with an
investment of $30 million.
Our Take
With this deal, Forest Labs is
looking to strengthen its presence in the cardiovascular market and
hospital segment. With currently available treatments not producing
meaningful improvements in patient outcomes, the ADHF market
represents significant commercial potential.
Forest Labs currently carries a
Zacks Rank #3 (Hold). The company is facing tough times with
Lexapro losing patent protection. Namenda will face generic
competition in early 2015 putting another $1+ billion at risk.
Meanwhile, the performance of new products, especially Teflaro, has
been below expectations. We also remain concerned about rising
expenses. However, we remain encouraged by the company’s progress
with its pipeline candidates.
Companies that look
better-positioned include Catalyst Pharmaceuticals Partners
Inc. (CPRX), Santarus, Inc. (SNTS) and
Jazz Pharmaceuticals (JAZZ). All three are Zacks
Rank #1 (Strong Buy) stocks.
CATALYST PHARMA (CPRX): Free Stock Analysis Report
FOREST LABS A (FRX): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
SANTARUS INC (SNTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024